Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 in obesity and type 2 diabetes with overweight/obesity
NCT06567041Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing NNC0519-0130 with Placebo (2 arms). Primary endpoint: Adverse Events at 253 days. Started Aug 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06567041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567041.